Oncology Poster Tour

Author(s)

Rose Wickstead, MPharm MSc (Health Economics), PGCert (Clinical Pharmacy), Costello Medical, London, UK

Posters featured in this tour:

PT31: A Time Series Analysis of Immune Checkpoint Inhibitors Use in Italian Population: 2017-2022
PT32: Cost-Effectiveness of Lorlatinib in Second-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer in China
PT33: Cost-Effectiveness of Pembrolizumab Plus Chemotherapy, With or Without Bevacizumab for the First-Line Treatment of PD-L1-Positive Patients With Persistent, Recurrent, or Metastatic Cervical Cancer in France
PT34: Impact in Health Outcomes of PD-(L)1 Inhibitors to Treat Early Stages Cancers in Switzerland
PT35: Matching-Adjusted Indirect Comparison (MAIC) of Dabrafenib Plus Trametinib Versus Pembrolizumab Plus Chemotherapy in Patients with Treatment-Naive Metastatic BRAF V600 Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
PT36: Real-World Analysis on Therapeutic Pattern and Economic Burden of Androgen-Receptor Signaling Inhibitors (ARSI) and Taxane-Based Chemotherapy Treated Metastatic Castration-Resistant Prostate Cancer Patients in Italy

2023-11, ISPOR Europe 2023, Copenhagen, Denmark

213